Literature DB >> 8589684

Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA.

I Santisteban1, F X Arredondo-Vega, S Kelly, M Loubser, N Meydan, C Roifman, P L Howell, T Bowen, K I Weinberg, M L Schroeder.   

Abstract

We report three novel adenosine deaminase (ADA) mutations with interesting implications. A Somali child with severe combined immunodeficiency disease (SCID) had reduced ADA mRNA in T cells and was homozygous for the nonsense mutation Q3X. Unexpectedly, her healthy father was a compound ADA heterozygote whose second allele carried a 'partial' mutation, R142Q, due to a G-->A transition of a CpG dinucleotide. A C-->T transition of the same CpG produced a nonsense mutation, R142X, in two homozygous Canadian Mennonite infants with SCID. The severe and healthy phenotypes associated with R142X and R142Q, the high frequency of 'partial' ADA mutations arising from CpGs in healthy individuals of African descent and the presence of CAA (glutamine) at codon 142 in murine ADA, suggest selection for replacement of this CpG hotspot by CpA during ADA evolution. R142X, located within a purine-rich segment at nt 62/116 of exon 5, caused skipping of the exon, possibly by disrupting a splicing enhancer. Absence of exon 5 in T cell ADA mRNA and low ADA activity in T cells and erythrocytes obtained at age 18-22 months from one of the Mennonite children, indicate limited expression of a normal ADA cDNA from retrovirally transduced CD34+ umbilical cord leukocytes infused shortly after birth in an attempt at stem cell gene therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589684     DOI: 10.1093/hmg/4.11.2081

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  A premature termination codon interferes with the nuclear function of an exon splicing enhancer in an open reading frame-dependent manner.

Authors:  A Gersappe; D J Pintel
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Authors:  L Murguia-Favela; W Min; R Loves; M Leon-Ponte; E Grunebaum
Journal:  Clin Exp Immunol       Date:  2020-02-09       Impact factor: 4.330

3.  An RNA splicing enhancer-like sequence is a component of a splicing inhibitor element from Rous sarcoma virus.

Authors:  L M McNally; M T McNally
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Defects in RNA splicing and the consequence of shortened translational reading frames.

Authors:  L E Maquat
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

Review 5.  The regulation of splice-site selection, and its role in human disease.

Authors:  T A Cooper; W Mattox
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

6.  Nearby stop codons in exons of the neurofibromatosis type 1 gene are disparate splice effectors.

Authors:  S Hoffmeyer; P Nürnberg; H Ritter; R Fahsold; W Leistner; D Kaufmann; W Krone
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

7.  Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.

Authors:  Antonia Kwan; Roshini S Abraham; Robert Currier; Amy Brower; Karen Andruszewski; Jordan K Abbott; Mei Baker; Mark Ballow; Louis E Bartoshesky; Francisco A Bonilla; Charles Brokopp; Edward Brooks; Michele Caggana; Jocelyn Celestin; Joseph A Church; Anne Marie Comeau; James A Connelly; Morton J Cowan; Charlotte Cunningham-Rundles; Trivikram Dasu; Nina Dave; Maria T De La Morena; Ulrich Duffner; Chin-To Fong; Lisa Forbes; Debra Freedenberg; Erwin W Gelfand; Jaime E Hale; I Celine Hanson; Beverly N Hay; Diana Hu; Anthony Infante; Daisy Johnson; Neena Kapoor; Denise M Kay; Donald B Kohn; Rachel Lee; Heather Lehman; Zhili Lin; Fred Lorey; Aly Abdel-Mageed; Adrienne Manning; Sean McGhee; Theodore B Moore; Stanley J Naides; Luigi D Notarangelo; Jordan S Orange; Sung-Yun Pai; Matthew Porteus; Ray Rodriguez; Neil Romberg; John Routes; Mary Ruehle; Arye Rubenstein; Carlos A Saavedra-Matiz; Ginger Scott; Patricia M Scott; Elizabeth Secord; Christine Seroogy; William T Shearer; Subhadra Siegel; Stacy K Silvers; E Richard Stiehm; Robert W Sugerman; John L Sullivan; Susan Tanksley; Millard L Tierce; James Verbsky; Beth Vogel; Rosalyn Walker; Kelly Walkovich; Jolan E Walter; Richard L Wasserman; Michael S Watson; Geoffrey A Weinberg; Leonard B Weiner; Heather Wood; Anne B Yates; Jennifer M Puck; Vincent R Bonagura
Journal:  JAMA       Date:  2014-08-20       Impact factor: 56.272

8.  Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.

Authors:  N Shiga; Y Takeshima; H Sakamoto; K Inoue; Y Yokota; M Yokoyama; M Matsuo
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

9.  Treatment of spinal muscular atrophy by sodium butyrate.

Authors:  J G Chang; H M Hsieh-Li; Y J Jong; N M Wang; C H Tsai; H Li
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

10.  Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles.

Authors:  F X Arredondo-Vega; I Santisteban; S Daniels; S Toutain; M S Hershfield
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.